Immuno-Oncology Diagnostics. Market Forecasts for Immuno-Oncology Diagnostics by Assay Type, Technology, Client, and Country with Executive/Consultant Guides 2026 to 2030 (4th Edition)

Diagnostics plays new key role in Therapeutic Development and Clinical Trials. AI pushes development timeline…

Immuno-oncology (IO) diagnostics are in vitro diagnostic tests used to identify biomarkers that predict patient response to immunotherapies. These therapies stimulate or restore the immune system’s ability to recognize and destroy cancer cells and have become one of the most important advances in oncology over the past decade. As immunotherapies increasingly become standard treatment options across multiple tumor types, diagnostic tests that guide patient selection have become critical components of clinical decision-making.

The IO diagnostics market has developed in parallel with the rapid expansion of immunotherapy drug classes, including immune checkpoint inhibitors, CAR-T cell therapies, bispecific antibodies, and therapeutic cancer vaccines. Unlike traditional targeted therapies that focus on specific genetic mutations, immunotherapies rely on complex interactions between tumors and the immune system. As a result, IO diagnostics often require evaluation of multiple biological parameters including protein expression, immune cell infiltration, tumor mutational burden, and gene expression signatures.

The global immuno-oncology therapeutics market has demonstrated substantial growth, exceeding approximately USD 200 billion in recent years and projected to continue expanding as additional checkpoint inhibitors, cell therapies, and combination therapies are introduced. This growth is driving demand for predictive biomarker testing capable of identifying patients most likely to benefit from immune-based treatments.

Role of Biomarkers in Immuno-Oncology

Biomarkers play a central role in guiding immunotherapy treatment decisions. One of the most widely used biomarkers is PD-L1 expression, which is commonly assessed using immunohistochemistry (IHC) assays. PD-L1 testing is used to determine eligibility for checkpoint inhibitor therapies targeting PD-1 or PD-L1 pathways in cancers such as non-small cell lung cancer, melanoma, bladder cancer, and head and neck cancer.

Other important biomarkers include tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repair deficiency (dMMR), and gene expression profiles that characterize immune system activity within the tumor microenvironment. High tumor mutational burden or MSI-high status may indicate increased likelihood of response to immune checkpoint inhibitors due to greater neoantigen presentation.

Emerging biomarkers include immune gene signatures, tumor-infiltrating lymphocyte (TIL) density measurements, and circulating biomarkers detected through liquid biopsy technologies. These approaches aim to improve predictive accuracy beyond single biomarker testing.

Technologies Used in IO Diagnostics

The IO diagnostics market incorporates a range of molecular and immunological testing technologies. Immunohistochemistry remains one of the most widely used methods due to its ability to detect protein expression patterns within tissue samples. IHC assays are commonly used to measure PD-L1 expression and other immune-related markers.

Next-generation sequencing (NGS) technologies enable comprehensive genomic profiling, allowing simultaneous detection of multiple biomarkers including TMB, MSI, and gene expression signatures. NGS panels can support both companion diagnostics and broader tumor profiling approaches.

Polymerase chain reaction (PCR) technologies continue to play an important role in detecting specific genetic alterations and microsatellite instability. Digital pathology and image analysis technologies are increasingly used to quantify immune cell infiltration and biomarker expression patterns.

Liquid biopsy technologies represent an emerging segment of the IO diagnostics market. These tests analyze circulating tumor DNA or other biomarkers in blood samples, enabling less invasive monitoring of disease progression and treatment response.

Market Drivers

Several factors are driving growth in the immuno-oncology diagnostics market. One of the most significant drivers is the continued expansion of immunotherapy drug pipelines. Pharmaceutical companies are investing heavily in checkpoint inhibitors, cell therapies, and combination immunotherapies that require biomarker testing to guide patient selection.

Increasing adoption of precision medicine approaches is also supporting demand for IO diagnostics. Clinicians are increasingly using biomarker information to tailor treatment decisions based on individual patient characteristics.

Advances in genomic sequencing technologies and bioinformatics tools have improved the sensitivity and specificity of biomarker detection, supporting broader clinical adoption.

The growing use of combination therapies is also increasing the need for more complex biomarker testing strategies capable of evaluating multiple immune pathways simultaneously.

Market Segmentation

The IO diagnostics market can be segmented by technology platform, cancer type, end user, and geographic region.

By technology, immunohistochemistry remains widely used, while next-generation sequencing represents one of the fastest-growing segments due to its ability to evaluate multiple biomarkers simultaneously.

By cancer type, lung cancer represents one of the largest segments due to widespread use of checkpoint inhibitors in non-small cell lung cancer. Other important segments include melanoma, bladder cancer, breast cancer, colorectal cancer, and head and neck cancer.

End users include hospital laboratories, reference laboratories, academic research centers, and pharmaceutical companies conducting clinical trials.

North America represents the largest geographic market due to advanced healthcare infrastructure and high adoption of immunotherapy treatments. Europe and Asia-Pacific are also experiencing increasing demand for IO diagnostic testing.

Competitive Landscape

The immuno-oncology diagnostics market includes large in vitro diagnostics companies, molecular diagnostics firms, and specialized biotechnology companies focused on biomarker discovery.

Many diagnostic developers partner with pharmaceutical companies to co-develop companion diagnostic tests aligned with specific immunotherapy drugs. Strategic collaborations are common due to the need for coordinated clinical validation and regulatory approval.

Companies are increasingly focused on developing multiplex testing platforms capable of supporting multiple biomarker types across therapeutic indications.

Data analytics and bioinformatics capabilities are becoming important competitive differentiators as biomarker interpretation becomes more complex.

Future Outlook

The immuno-oncology diagnostics market is expected to continue expanding as immunotherapies become standard treatments across additional cancer types and earlier lines of therapy.

Emerging technologies such as spatial biology, multiplex imaging, and artificial intelligence-based biomarker analysis may improve predictive accuracy and support development of more personalized treatment strategies.

Liquid biopsy technologies may expand testing volumes by enabling non-invasive monitoring of treatment response.

Overall, IO diagnostics are expected to remain a critical component of precision oncology, supporting more effective patient selection and improved clinical outcomes as immunotherapy continues to evolve.